Subcutaneous Epcoritamab in Combination with Rituximab plus Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

被引：8

作者：

Falchi, Lorenzo ^{[1
]}

Leslie, Lori A. ^{[2
]}

Belada, David ^{[3
]}

Kopeckova, Katerina ^{[4
]}

Offner, Fritz ^{[5
]}

Brody, Joshua ^{[6
]}

Canales, Miguel ^{[7
]}

Martin Garcia-Sancho, Alejandro ^{[8
]}

Nijland, Marcel ^{[9
,10
]}

Andersson, P-O ^{[11
]}

Awan, Farrukh T. ^{[12
]}

Christensen, Jacob Haaber ^{[13
]}

Drott, Kristina ^{[14
]}

Hellstrom, Mats ^{[15
]}

Lewerin, Catharina ^{[16
]}

Narkhede, Mayur ^{[17
]}

Snauwaert, Sylvia ^{[18
]}

Wahlin, Bjorn E. ^{[19
]}

Rana, Ali ^{[20
]}

Abbas, Aqeel ^{[20
]}

Wang, Liwei ^{[20
]}

Minh Dinh ^{[21
]}

Vermaat, Joost S. P. ^{[22
]}

Abrisqueta, Pau ^{[23
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA

[2] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[3] Charles Univ Prague, Hosp & Fac Med, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[4] Fak Nemocnice Motole, Prague, Czech Republic

[5] Univ Ziekenhuis Gent, Ghent, Belgium

[6] Icahn Sch Med Mt Sinai, New York, NY USA

[7] Hosp Univ La Paz, Madrid, Spain

[8] Hosp Univ Salamanca, Salamanca, Spain

[9] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[10] Univ Groningen, Groningen, Netherlands

[11] Sodra Alvsborgs Sjukhus, Boras, Sweden

[12] Univ Texas Southwestern Med Ctr, Dallas, TX USA

[13] Odense Univ Hosp, Odense, Denmark

[14] Skane Univ Hosp, Lund, Sweden

[15] Uppsala Univ Hosp, Uppsala, Sweden

[16] Sahlgrens Univ Hosp, Gothenburg, Sweden

[17] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[18] AZ Sint Jan Brugge, Dept Hematol, Brugge, Belgium

[19] Karolinska Inst, Stockholm, Sweden

[20] Genmab, Princeton, NJ USA

[21] AbbVie Inc, N Chicago, IL USA

[22] Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands

[23] Hosp Univ Vall dHebron, Barcelona, Spain

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158232

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1471 / 1473

页数：3

共 50 条

[41] Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study
Tilly, Herve
Morschhauser, Franck
Casasnovas, Olivier
Molina, Thierry Jo
Feugier, Pierre
Le Gouill, Steven
Haioun, Corinne
Tournilhac, Olivier
Bouabdallah, Reda
Gabarre, Jean
Lamy, Thierry
Cabecadas, Jose
Becker, Stephanie
Jardin, Fabrice
Mounier, Nicolas
Salles, Gilles
LANCET HAEMATOLOGY, 2018, 5 (09): : E403 - E410
[42] Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma
Chihara, Dai
Nastoupil, Loretta
Strati, Paolo
Samaniego, Felipe
Feng, Lei
Rodriguez, Maria Alma
Fayad, Luis
Westin, Jason R.
Hagemeister, Fredrick B.
Wang, Michael
Neelapu, Sattva S.
Fowler, Nathan H.
BLOOD, 2021, 138
[43] SUBCUTANEOUS RITUXIMAB AND CHEMOTHERAPY ACHIEVES SIMILAR TROUGH LEVELS, SAFETY, AND RESPONSE AS INTRAVENOUS RITUXIMAB IN FIRST-LINE FOLLICULAR LYMPHOMA: STAGE 1 RESULTS OF THE PHASE 3 SABRINA STUDY
Davies, A.
Merli, F.
Mihaljevic, B.
Siritanaratkul, N.
Solal-Celigny, P.
Boehnke, A.
Berge, C.
McIntyre, C.
Barrett, M.
MacDonald, D.
HAEMATOLOGICA, 2013, 98 : 131 - 132
[44] Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
Vitolo, Umberto
Merli, Michele
Norasetthada, Lalita
Wassenaar, Timothy Robert
Martin, Eva Maria Donato
Bobillo, Sabela
Shen, Biyi
Flink, Dina M.
Zhu, Min
Chandrasekharan, Soujanya
Brouwer-Visser, Jurriaan
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth R.
Cordoba, Raul
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study
Fowler, Nathan
Nastoupil, Loretta
de Vos, Sven
Knapp, Mark
Flinn, Ian W.
Chen, Robert
Advani, Ranjana H.
Bhatia, Sumeet
Martin, Peter
Mena, Raul
Suzuki, Samuel
Beaupre, Darrin M.
Neuenburg, Jutta K.
Palomba, M. Lia
BLOOD, 2015, 126 (23)
[46] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
Eliazar Sabater
Armando López-Guillermo
Antonio Rueda
Antonio Salar
Itziar Oyagüez
Juan Manuel Collar
Applied Health Economics and Health Policy, 2016, 14 : 465 - 477
[47] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
Sabater, Eliazar
Lopez-Guillermo, Armando
Rueda, Antonio
Salar, Antonio
Oyaguez, Itziar
Manuel Collar, Juan
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (04) : 465 - 477
[48] PERSPECTIVE: A Randomized, Phase 3 Study of Ibrutinib-Rituximab Versus Placebo-Rituximab Combination Therapy for First-Line Treatment of Follicular Lymphoma
Flinn, Ian
Gordon, Leo
Rule, Simon
Chen, Robert
Kwei, Long
Chu, Alvina
Fowler, Nathan
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S12 - S13
[49] Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)
Sacchi, Stefano
Pozzi, Samantha
Cesaretti, Marina
Marcheselli, Luigi
Liardo, Eliana Valentina
Buda, Gabriele
Lazzaro, Antonio
Baldini, Luca
Di Raimondo, Francesco
Musto, Pellegrino
Zaccaria, Alfonso
Specchia, Giorgina
Vitolo, Umberto
Magagnoli, Massimo
Silvestris, Franco
Fattori, Pier Paolo
Tosi, Patrizia
Carella, Angelo Michele
BLOOD, 2012, 120 (21)
[50] Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, OpenLabel, Phase 1b Trial
Strati, Paolo
Christian, Beth
Martin, Peter
Champion, Becky
Coleman, Morton
Agajanian, Richy
Smith, Sonali M.
Venugopal, Parameswaran
Lossos, Izidore S.
Kridel, Robert
Calvo, Roser
Higgins, Kara
Stephens, Deborah M.
BLOOD, 2022, 140 : 3606 - 3608

← 1 2 3 4 5 →